Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
Reuters NewMedia - December 19, 2005
The world's biggest supplier of AIDS medicines said brecanavir, formerly known as GW640385, had shown potent antiviral activity after 24 weeks in a clinical study involving 31 patients.
Brecanavir belongs to a class of HIV drugs known as protease inhibitors, which have formed a central plank of triple combination therapy since the 1990s. As a new agent, it may be useful in treating patients infected with strains of HIV that have become resistant to other protease inhibitors.
Results presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington showed 81 percent of patients on a drug regimen including brecanavir had levels of virus in their blood that were undetectable by standard tests after 24 weeks of treatment.
The response rate was similar whether or not patients were resistant to other protease inhibitors.
The encouraging results for the drug, which Glaxo is co-developing with Vertex Pharmaceuticals Inc., follow a setback for another experimental HIV compound that was dropped from development in October.
Aplaviroc belonged to a new class of HIV medicines called CCR5 inhibitors and had already started Phase III tests before Glaxo found it could cause serious liver problems in a small number of patients.
051219
RE051229
Copyright © 2005 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .